Search

Displaying results 2211 - 2220 of 8575 in total
  1. Drug

    Edetate calcium disodium anhydrous

    go.drugbank.com/drugs/DB14598
    ApprovedInvestigational

    [A204173] Edetate calcium disodium was granted FDA approval on 16 July 1953.[L12774]

    Products: Calcium Disodium Versenate Liq 200mg/ml
  2. Drug

    Nitroprusside

    go.drugbank.com/drugs/DB00325
    ApprovedInvestigational

    Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles).

  3. Drug

    Meprobamate

    go.drugbank.com/drugs/DB00371
    ApprovedIllicit

    Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). … It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines.

    Products: Meditran 400mg, Novo-mepro 400mg
  4. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.

  5. Drug

    Fenofibric acid

    go.drugbank.com/drugs/DB13873
    ApprovedInvestigational

    [A32038,L12855] Due to its high hydrophilicity and poor absorption profile,[A32038] prodrug ,[fenofibrate], and other conjugated compounds of fenofibric acid, such as choline fenofibrate, have been developed

  6. Drug

    Linaclotide

    go.drugbank.com/drugs/DB08890
    ApprovedInvestigational

    Linaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.

  7. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.

  8. Drug

    H3B-8800

    go.drugbank.com/drugs/DB14017
    Investigational

    H3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting [A32749

  9. Drug

    Delorazepam

    go.drugbank.com/drugs/DB01511
    IllicitInvestigational

    It may have adverse effects such as drowsiness, and cognitive impairments such as short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. … It has been approved for marketing in Italy.

  10. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Currently, tianeptine is approved in France and manufactured and marketed by Laboratories Servier SA; it is also marketed in several other European countries under the trade name “Coaxil” as well as in … Tianeptine was discovered and patented by The French Society of Medical Research in the 1960s [L2946].